These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22232738)

  • 1. ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.
    Smith AM; Findlay VJ; Bandurraga SG; Kistner-Griffin E; Spruill LS; Liu A; Golshayan AR; Turner DP
    Carcinogenesis; 2012 Mar; 33(3):572-80. PubMed ID: 22232738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.
    Kato T; Fujita Y; Nakane K; Kojima T; Nozawa Y; Deguchi T; Ito M
    Biochem Biophys Res Commun; 2012 Jan; 417(3):966-71. PubMed ID: 22206665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
    Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
    Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Naito S
    Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ETS1 induces transforming growth factor β signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells.
    Rodgers JJ; McClure R; Epis MR; Cohen RJ; Leedman PJ; Harvey JM; ; Thomas MA; Bentel JM
    J Cell Biochem; 2019 Jan; 120(1):848-860. PubMed ID: 30161276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
    Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
    J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer.
    Huang EC; Chen G; Baek SJ; McEntee MF; Collier JJ; Minkin S; Biggerstaff J; Whelan J
    Nutr Cancer; 2011 Nov; 63(8):1287-96. PubMed ID: 21958043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways.
    Chung S; Furihata M; Tamura K; Uemura M; Daigo Y; Nasu Y; Miki T; Shuin T; Fujioka T; Nakamura Y; Nakagawa H
    Oncogene; 2009 Aug; 28(32):2849-59. PubMed ID: 19483721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.
    Donovan MJ; Osman I; Khan FM; Vengrenyuk Y; Capodieci P; Koscuiszka M; Anand A; Cordon-Cardo C; Costa J; Scher HI
    BJU Int; 2010 Feb; 105(4):462-7. PubMed ID: 19624594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells.
    Preece DM; Harvey JM; Bentel JM; Thomas MA
    Prostate; 2011 Mar; 71(4):403-14. PubMed ID: 20842667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.
    Shiota M; Yokomizo A; Naito S
    J Mol Endocrinol; 2011 Aug; 47(1):R25-41. PubMed ID: 21504942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate for castration resistant prostate cancer.
    Shah S; Ryan C
    Expert Opin Investig Drugs; 2010 Apr; 19(4):563-70. PubMed ID: 20225998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.
    Mink SR; Hodge A; Agus DB; Jain A; Gross ME
    Prostate; 2010 Aug; 70(11):1201-10. PubMed ID: 20564426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor and invasion in prostate cancer.
    Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
    Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.